Ruzurgi

Active Ingredient(s): Amifampridine
FDA Approved: * May 6, 2019
Pharm Company: * JACOBUS PHARM CO INC
Category: Immune System

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ruzurgi Overview

Amifampridine (pyridine-3,4-diamine, 3,4-diaminopyridine, 3,4-DAP) is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form. Around 2000 doctors at A...

Read more Ruzurgi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Amifampridine

Recent Ruzurgi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Amifampridine
  • Tablet: 10mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ruzurgi: (1 result)

Sorted by National Drug Code
  • 49938-110 Ruzurgi 10 mg Oral Tablet by Jacobus Pharmaceutical Company, Inc.

Other drugs which contain Amifampridine or a similar ingredient: (2 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 12 December 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA